A Phase 1, Randomized, Single-Blind, Placebo Controlled, Single-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-TTRSC02 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2017
At a glance
- Drugs ALN TTRsc02 (Primary)
- Indications Amyloidosis
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 10 Feb 2017 Planned End Date changed from 1 Oct 2017 to 1 Mar 2018.
- 10 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.
- 02 Nov 2016 Initial clinical results from this study will be presented at the R&D Day, according to an Alnylam Pharmaceuticals media release,